List of Excipients in API hydrocortisone probutate
✉ Email this page to a colleague
Excipients in NDA-approved (novel) drugs containing hydrocortisone probutate
Detailed excipient profiles for hydrocortisone probutate
Excipient focus: ANHYDROUS CITRIC ACID
hydrocortisone probutate drug variants containing ANHYDROUS CITRIC ACID
| Company | Ingredient | NDC |
|---|---|---|
| ANI Pharmaceuticals Inc | hydrocortisone probutate | 62559-325 |
| >Company | >Ingredient | >NDC |
hydrocortisone probutate drug variants not containing ANHYDROUS CITRIC ACID
| Company | Ingredient | NDC |
|---|---|---|
| PharmaDerm a division of Fougera Pharmaceuticals Inc | hydrocortisone probutate | 10337-153 |
| >Company | >Ingredient | >NDC |
Excipient focus: ANHYDROUS TRISODIUM CITRATE
hydrocortisone probutate drug variants containing ANHYDROUS TRISODIUM CITRATE
| Company | Ingredient | NDC |
|---|---|---|
| PharmaDerm a division of Fougera Pharmaceuticals Inc | hydrocortisone probutate | 10337-153 |
| ANI Pharmaceuticals Inc | hydrocortisone probutate | 62559-325 |
| >Company | >Ingredient | >NDC |
hydrocortisone probutate drug variants not containing ANHYDROUS TRISODIUM CITRATE
| Company | Ingredient | NDC |
|---|---|---|
| >Company | >Ingredient | >NDC |
Excipient focus: BUTYLPARABEN
hydrocortisone probutate drug variants containing BUTYLPARABEN
| Company | Ingredient | NDC |
|---|---|---|
| PharmaDerm a division of Fougera Pharmaceuticals Inc | hydrocortisone probutate | 10337-153 |
| ANI Pharmaceuticals Inc | hydrocortisone probutate | 62559-325 |
| >Company | >Ingredient | >NDC |
hydrocortisone probutate drug variants not containing BUTYLPARABEN
| Company | Ingredient | NDC |
|---|---|---|
| >Company | >Ingredient | >NDC |
Excipient focus: CITRIC ACID MONOHYDRATE
hydrocortisone probutate drug variants containing CITRIC ACID MONOHYDRATE
| Company | Ingredient | NDC |
|---|---|---|
| PharmaDerm a division of Fougera Pharmaceuticals Inc | hydrocortisone probutate | 10337-153 |
| >Company | >Ingredient | >NDC |
hydrocortisone probutate drug variants not containing CITRIC ACID MONOHYDRATE
| Company | Ingredient | NDC |
|---|---|---|
| ANI Pharmaceuticals Inc | hydrocortisone probutate | 62559-325 |
| >Company | >Ingredient | >NDC |
Excipient focus: GLYCERYL MONOSTEARATE
hydrocortisone probutate drug variants containing GLYCERYL MONOSTEARATE
| Company | Ingredient | NDC |
|---|---|---|
| PharmaDerm a division of Fougera Pharmaceuticals Inc | hydrocortisone probutate | 10337-153 |
| ANI Pharmaceuticals Inc | hydrocortisone probutate | 62559-325 |
| >Company | >Ingredient | >NDC |
hydrocortisone probutate drug variants not containing GLYCERYL MONOSTEARATE
| Company | Ingredient | NDC |
|---|---|---|
| >Company | >Ingredient | >NDC |
Excipient focus: GLYCERYL STEARATE SE
hydrocortisone probutate drug variants containing GLYCERYL STEARATE SE
| Company | Ingredient | NDC |
|---|---|---|
| PharmaDerm a division of Fougera Pharmaceuticals Inc | hydrocortisone probutate | 10337-153 |
| ANI Pharmaceuticals Inc | hydrocortisone probutate | 62559-325 |
| >Company | >Ingredient | >NDC |
hydrocortisone probutate drug variants not containing GLYCERYL STEARATE SE
| Company | Ingredient | NDC |
|---|---|---|
| >Company | >Ingredient | >NDC |
Excipient focus: LIGHT MINERAL OIL
hydrocortisone probutate drug variants containing LIGHT MINERAL OIL
| Company | Ingredient | NDC |
|---|---|---|
| PharmaDerm a division of Fougera Pharmaceuticals Inc | hydrocortisone probutate | 10337-153 |
| ANI Pharmaceuticals Inc | hydrocortisone probutate | 62559-325 |
| >Company | >Ingredient | >NDC |
hydrocortisone probutate drug variants not containing LIGHT MINERAL OIL
| Company | Ingredient | NDC |
|---|---|---|
| >Company | >Ingredient | >NDC |
Excipient focus: METHYLPARABEN
hydrocortisone probutate drug variants containing METHYLPARABEN
| Company | Ingredient | NDC |
|---|---|---|
| PharmaDerm a division of Fougera Pharmaceuticals Inc | hydrocortisone probutate | 10337-153 |
| ANI Pharmaceuticals Inc | hydrocortisone probutate | 62559-325 |
| >Company | >Ingredient | >NDC |
hydrocortisone probutate drug variants not containing METHYLPARABEN
| Company | Ingredient | NDC |
|---|---|---|
| >Company | >Ingredient | >NDC |
Excipient focus: PEG-20 STEARATE
hydrocortisone probutate drug variants containing PEG-20 STEARATE
| Company | Ingredient | NDC |
|---|---|---|
| PharmaDerm a division of Fougera Pharmaceuticals Inc | hydrocortisone probutate | 10337-153 |
| ANI Pharmaceuticals Inc | hydrocortisone probutate | 62559-325 |
| >Company | >Ingredient | >NDC |
hydrocortisone probutate drug variants not containing PEG-20 STEARATE
| Company | Ingredient | NDC |
|---|---|---|
| >Company | >Ingredient | >NDC |
Excipient focus: PETROLATUM
hydrocortisone probutate drug variants containing PETROLATUM
| Company | Ingredient | NDC |
|---|---|---|
| PharmaDerm a division of Fougera Pharmaceuticals Inc | hydrocortisone probutate | 10337-153 |
| >Company | >Ingredient | >NDC |
hydrocortisone probutate drug variants not containing PETROLATUM
| Company | Ingredient | NDC |
|---|---|---|
| ANI Pharmaceuticals Inc | hydrocortisone probutate | 62559-325 |
| >Company | >Ingredient | >NDC |
Excipient focus: POLYSORBATE 60
hydrocortisone probutate drug variants containing POLYSORBATE 60
| Company | Ingredient | NDC |
|---|---|---|
| PharmaDerm a division of Fougera Pharmaceuticals Inc | hydrocortisone probutate | 10337-153 |
| ANI Pharmaceuticals Inc | hydrocortisone probutate | 62559-325 |
| >Company | >Ingredient | >NDC |
hydrocortisone probutate drug variants not containing POLYSORBATE 60
| Company | Ingredient | NDC |
|---|---|---|
| >Company | >Ingredient | >NDC |
Excipient focus: PROPYLENE GLYCOL
hydrocortisone probutate drug variants containing PROPYLENE GLYCOL
| Company | Ingredient | NDC |
|---|---|---|
| PharmaDerm a division of Fougera Pharmaceuticals Inc | hydrocortisone probutate | 10337-153 |
| ANI Pharmaceuticals Inc | hydrocortisone probutate | 62559-325 |
| >Company | >Ingredient | >NDC |
hydrocortisone probutate drug variants not containing PROPYLENE GLYCOL
| Company | Ingredient | NDC |
|---|---|---|
| >Company | >Ingredient | >NDC |
Excipient focus: SORBITAN MONOSTEARATE
hydrocortisone probutate drug variants containing SORBITAN MONOSTEARATE
| Company | Ingredient | NDC |
|---|---|---|
| PharmaDerm a division of Fougera Pharmaceuticals Inc | hydrocortisone probutate | 10337-153 |
| ANI Pharmaceuticals Inc | hydrocortisone probutate | 62559-325 |
| >Company | >Ingredient | >NDC |
hydrocortisone probutate drug variants not containing SORBITAN MONOSTEARATE
| Company | Ingredient | NDC |
|---|---|---|
| >Company | >Ingredient | >NDC |
Excipient focus: STEARYL ALCOHOL
hydrocortisone probutate drug variants containing STEARYL ALCOHOL
| Company | Ingredient | NDC |
|---|---|---|
| PharmaDerm a division of Fougera Pharmaceuticals Inc | hydrocortisone probutate | 10337-153 |
| ANI Pharmaceuticals Inc | hydrocortisone probutate | 62559-325 |
| >Company | >Ingredient | >NDC |
hydrocortisone probutate drug variants not containing STEARYL ALCOHOL
| Company | Ingredient | NDC |
|---|---|---|
| >Company | >Ingredient | >NDC |
Excipient focus: WATER
hydrocortisone probutate drug variants containing WATER
| Company | Ingredient | NDC |
|---|---|---|
| PharmaDerm a division of Fougera Pharmaceuticals Inc | hydrocortisone probutate | 10337-153 |
| ANI Pharmaceuticals Inc | hydrocortisone probutate | 62559-325 |
| >Company | >Ingredient | >NDC |
hydrocortisone probutate drug variants not containing WATER
| Company | Ingredient | NDC |
|---|---|---|
| >Company | >Ingredient | >NDC |
Excipient focus: WHITE PETROLATUM
hydrocortisone probutate drug variants containing WHITE PETROLATUM
| Company | Ingredient | NDC |
|---|---|---|
| ANI Pharmaceuticals Inc | hydrocortisone probutate | 62559-325 |
| >Company | >Ingredient | >NDC |
hydrocortisone probutate drug variants not containing WHITE PETROLATUM
| Company | Ingredient | NDC |
|---|---|---|
| PharmaDerm a division of Fougera Pharmaceuticals Inc | hydrocortisone probutate | 10337-153 |
| >Company | >Ingredient | >NDC |
Make Better Decisions: Try a trial or see plans & pricing
Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.
© Copyright 2002-2024 thinkBiotech LLC
ISSN: 2162-2639
Privacy and Cookies
Terms & Conditions
Site Map
DrugPatentWatch Alternatives
LOE / Generic Entry Opportunies 2024 - 2025
NCE-1 Patent Challenge Dates 2024 - 2025
Trigger-based marketing for the life sciences
Get DrugPatentWatch Business Intelligence Reports at Amazon.com
DrugChatter - AI-based answers to questions about drugs
RxJam - Digital Marketing for Life Sciences
ISSN: 2162-2639
Privacy and Cookies
Terms & Conditions
Site Map
DrugPatentWatch Alternatives
LOE / Generic Entry Opportunies 2024 - 2025
NCE-1 Patent Challenge Dates 2024 - 2025
Trigger-based marketing for the life sciences
Get DrugPatentWatch Business Intelligence Reports at Amazon.com
DrugChatter - AI-based answers to questions about drugs
RxJam - Digital Marketing for Life Sciences
Preferred Citation:
Friedman, Yali. "DrugPatentWatch" DrugPatentWatch, thinkBiotech, 2024, www.DrugPatentWatch.com.
See Primary Research Papers Citing DrugPatentWatch
Links
Follow DrugPatentWatch:
